Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Overactive Bladder Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Overactive Bladder Overview | 11 | 1 |
| Pipeline Products for Overactive Bladder Comparative Analysis | 12 | 1 |
| Overactive Bladder Therapeutics under Development by Companies | 13 | 2 |
| Overactive Bladder Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Overactive Bladder Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Overactive Bladder Products under Development by Companies | 19 | 2 |
| Overactive Bladder Products under Investigation by Universities/Institutes | 21 | 1 |
| Overactive Bladder Companies Involved in Therapeutics Development | 22 | 25 |
| Addex Therapeutics Ltd | 22 | 1 |
| Allergan Plc | 23 | 1 |
| Asahi Kasei Pharma Corp. | 24 | 1 |
| Astellas Pharma Inc. | 25 | 1 |
| Dompe Farmaceutici S.p.A. | 26 | 1 |
| Dong-A Socio Holdings Co. Ltd. | 27 | 1 |
| FemmePharma Global Healthcare, Inc. | 28 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 29 | 1 |
| Hydra Biosciences, Inc. | 30 | 1 |
| Ion Channel Innovations, LLC | 31 | 1 |
| Ipsen S.A. | 32 | 1 |
| Jeil Pharmaceutical Co., Ltd. | 33 | 1 |
| Juniper Pharmaceuticals, Inc. | 34 | 1 |
| Lipella Pharmaceuticals, Inc. | 35 | 1 |
| Merck &Co., Inc. | 36 | 1 |
| Mezzion Pharma Co. Ltd. | 37 | 1 |
| Ono Pharmaceutical Co., Ltd. | 38 | 1 |
| Recordati S.p.A. | 39 | 1 |
| Sanofi | 40 | 1 |
| Seoul Pharma Co., Ltd. | 41 | 1 |
| Taris Biomedical LLC | 42 | 1 |
| TheraVida, Inc. | 43 | 1 |
| Toray Industries, Inc. | 44 | 1 |
| UroGen Pharmaceuticals, Ltd. | 45 | 1 |
| XuanZhu Pharma Co., Ltd. | 46 | 1 |
| Overactive Bladder Therapeutics Assessment | 47 | 10 |
| Assessment by Monotherapy Products | 47 | 1 |
| Assessment by Combination Products | 48 | 1 |
| Assessment by Target | 49 | 2 |
| Assessment by Mechanism of Action | 51 | 2 |
| Assessment by Route of Administration | 53 | 2 |
| Assessment by Molecule Type | 55 | 2 |
| Drug Profiles | 57 | 48 |
| (mirabegron + solifenacin succinate) Drug Profile | 57 | 2 |
| (solifenacin succinate + tamsulosin hydrochloride) Drug Profile | 59 | 1 |
| abobotulinumtoxin A Drug Profile | 60 | 4 |
| ADX-71441 Drug Profile | 64 | 3 |
| DA-8010 Drug Profile | 67 | 1 |
| DFL-23448 Drug Profile | 68 | 1 |
| fadanafil Drug Profile | 69 | 1 |
| HC-067047 Drug Profile | 70 | 1 |
| HIP-1503 Drug Profile | 71 | 1 |
| mirabegron ER Drug Profile | 72 | 3 |
| onabotulinumtoxin A Drug Profile | 75 | 5 |
| onabotulinumtoxinA Drug Profile | 80 | 2 |
| onabotulinumtoxinA SR Drug Profile | 82 | 1 |
| ONO-8577 Drug Profile | 83 | 1 |
| oxybutynin chloride Drug Profile | 84 | 1 |
| oxybutynin chloride Drug Profile | 85 | 1 |
| Peptide to Antagonize PACAP Receptor for Pelvic Pain Syndrome and Overactive Bladder Drug Profile | 86 | 1 |
| pVAX-hSlo Drug Profile | 87 | 1 |
| REC-0438 Drug Profile | 88 | 1 |
| SAR-244181 Drug Profile | 89 | 1 |
| Small Molecule to Block TRPV1 for Overactive Bladder Drug Profile | 90 | 1 |
| Small Molecules to Antagonize EP1 Receptor for Overactive Bladder Drug Profile | 91 | 1 |
| solabegron hydrochloride Drug Profile | 92 | 2 |
| solifenacin succinate Drug Profile | 94 | 2 |
| SPO-1406 Drug Profile | 96 | 1 |
| tacrolimus Drug Profile | 97 | 1 |
| TAR-302 Drug Profile | 98 | 1 |
| THVD-201 Drug Profile | 99 | 2 |
| udenafil Drug Profile | 101 | 3 |
| vibegron Drug Profile | 104 | 1 |
| Overactive Bladder Dormant Projects | 105 | 6 |
| Overactive Bladder Discontinued Products | 111 | 2 |
| Overactive Bladder Product Development Milestones | 113 | 10 |
| Featured News &Press Releases | 113 | 1 |
| Sep 27, 2016: Allergan to Present New Data at the American Urogynecologic Society Annual Meeting in Denver | 113 | 1 |
| May 03, 2016: Allergan Presents New Data on OnabotulinumtoxinA at the American Urological Association Meeting in San Diego | 113 | 1 |
| Mar 21, 2016: Juniper Pharmaceuticals Affirms Development Pathway for Oxybutynin Intra-vaginal Ring for Overactive Bladder in Women | 114 | 1 |
| Jan 11, 2016: Juniper Pharmaceuticals Submits Pre-IND Meeting Request for its First Intra-vaginal Ring Product | 115 | 1 |
| Oct 15, 2015: Allergan Announces New Long-Term OnabotulinumtoxinA Treatment Study Results at the American Urogynecologic Society Meeting | 115 | 1 |
| Jun 15, 2015: NeXeption Forms New Company Velicept Therapeutics Intends to Merge with AltheRx Pharmaceuticals to Advance Solabegron for the Treatment of Overactive Bladder | 116 | 1 |
| May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial | 116 | 2 |
| May 05, 2015: Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting | 118 | 1 |
| Dec 08, 2014: Lipella s Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial | 118 | 1 |
| Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder | 118 | 1 |
| Oct 17, 2013: AltheRx Pharmaceuticals is Granted U.S. Patent for Use of Solabegron in Combination with Antimuscarinics for the Treatment of Overactive Bladder | 119 | 1 |
| Sep 11, 2013: Allergan's BOTOX Receives Authorisation for the Treatment of Overactive Bladder in the UK | 120 | 1 |
| Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg | 121 | 1 |
| May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441 | 121 | 1 |
| May 17, 2013: Astellas's Betmiga Obtains NICE Recommendation For Restricted Use In Treatment Of Overactive Bladder | 122 | 1 |
| Appendix | 123 | 2 |
| Methodology | 123 | 1 |
| Coverage | 123 | 1 |
| Secondary Research | 123 | 1 |
| Primary Research | 123 | 1 |
| Expert Panel Validation | 123 | 1 |
| Contact Us | 123 | 1 |
| Disclaimer | 124 | 1 |